United States Patent 8,034,375 (NSCLC): How Broad Are the Claims and What Is the Landscape?
US Patent 8,034,375 claims a combination treatment method for non-small cell lung cancer (NSCLC) using:
- Albumin-coated, cremophor-free paclitaxel nanoparticles, and
- A platinum agent that is cisplatin or carboplatin, with multiple dose, scheduling, and particle-spec dependent limitations.
The independent claim is method claim 1, and all subsequent claims are method-dependent narrowing variations (platinum selection, administration timing, particle size, albumin:paclitaxel weight ratio, paclitaxel dose banding, and schedule).
What does the independent claim actually cover (Claim 1 scope)?
Claim 1 core limitation set
Claim 1 requires all of the following, in a single method for treating NSCLC in a human:
- Administration of a composition comprising nanoparticles
- Paclitaxel coated with albumin
- Free of cremophor
- Administration of a platinum-based agent
- Combination context
- The method “compris(es)” administering (i.e., the combination is part of the claimed method)
Claim 1 combination structure
The patent does not require:
- Any specific tumor stage as a condition of the base method (that appears later in dependent claim 9).
- Any explicit paclitaxel dose band (later claims define numeric ranges).
- Any specific nanoparticle size threshold (later claims define ≤200 nm).
- Any specific albumin:paclitaxel weight ratio threshold (later claims define <9:1, ≤9:1, ≤18:1).
- Any specific administration schedule (later claims define weekly vs three-week schedules).
Where the independent claim can still be narrow
Even though Claim 1 is structurally broad, it is functionally constrained by the formulation identity:
- The nanoparticles must have paclitaxel + albumin coating
- The formulation must be cremophor-free
- The platinum agent must be cisplatin or carboplatin
If a competitor uses albumin-paclitaxel nanoparticles but uses a formulation that still contains cremophor (or uses a paclitaxel nanoparticle platform that does not meet “free of cremophor”), it can fall outside the claim.
How do the dependent claims narrow the coverage? (Claim-by-claim structure)
Platinum agent narrowing
- Claim 2: platinum is carboplatin
- Claim 7: platinum is carboplatin
- Claim 14: (dependent on claim 13) platinum is carboplatin
- Claim 24: platinum is carboplatin and albumin is human serum albumin
- Claim 31: platinum is carboplatin
- Claim 33: platinum is cisplatin
- Claim 34: (dependent on claim 20) platinum is carboplatin
These dependencies create multiple “entry points” into claim scope for carboplatin and cisplatin arms, with carboplatin dominating the numeric schedule/dose sub-sets.
Administration timing
- Claim 3: nanoparticles + platinum administered simultaneously
- Claim 4: nanoparticles + platinum administered sequentially
This matters for label design, because timing can be engineered to argue non-infringement if the competitor’s protocol does not meet the “simultaneous” or “sequential” characterization as construed.
Nanoparticle size limitation
- Claim 5: average diameter ≤ about 200 nm
- Claim 20: same threshold (dependent on claim 5)
- Claim 27: same threshold (dependent on claim 26)
- Claim 34: does not add size; it is platinum dependent
If a competitor uses larger particles, Claim 5 and all size-dependent claims likely become irrelevant, but Claim 1 may still be asserted (because Claim 1 alone does not require ≤200 nm).
Albumin:paclitaxel weight ratio constraints
A ladder of ratio limits appears:
- Claim 6: albumin:paclitaxel < about 9:1 (dependent on claim 5)
- Claim 17: albumin:paclitaxel ≤ about 18:1 or less (dependent on claim 1)
- Claim 18: albumin:paclitaxel ≤ about 18:1 or less (dependent on claim 5)
- Claim 19: albumin:paclitaxel ≤ about 9:1 or less (dependent on claim 5)
- Claim 21: albumin:paclitaxel ≤ about 18:1 or less (dependent on claim 20)
- Claim 22: albumin:paclitaxel ≤ about 9:1 or less (dependent on claim 21)
- Claim 23: albumin:paclitaxel < about 9:1 (dependent on claim 22)
- Claim 24: carboplatin + albumin is human serum albumin
- Claims 29-30: ratchet further down
- Claim 29: albumin:paclitaxel ≤ about 9:1 or less (dependent on claim 28)
- Claim 30: albumin:paclitaxel < about 9:1 (dependent on claim 29)
- Claim 28: albumin:paclitaxel ≤ about 18:1 or less (dependent on claim 27)
- Claim 9 and 25 do not cover ratio; ratio is formulation-critical.
Implication: the patent’s narrowest “sweet spots” are:
- Particle size ≤200 nm plus
- Albumin:paclitaxel <9:1 and/or ≤9:1 and/or ≤18:1
But because ratio limits appear in multiple dependent chains, the competitor’s product can still infringe Claim 1 even if it misses the ratio thresholds, provided the other claim-1 formulation criteria are met (albumin-coated paclitaxel nanoparticles; cremophor-free) and the combination treatment uses cisplatin/carboplatin.
Albumin identity
- Claim 8: albumin is human serum albumin
This claim is a direct formulation identity limitation; if a competitor uses non-human albumin or recombinant variants, it may avoid the claim-8-specific dependency.
Cancer stage
- Claim 9: cancer is advanced stage
- Claim 25: (dependent on claim 15) cancer is advanced stage
Stage limitation only affects those dependent claims. Claim 1 itself does not require “advanced stage.”
Paclitaxel dose banding
The patent defines multiple dose windows tied to schedules:
- Claim 10: paclitaxel dose about 50 to about 400 mg/m2
- Claim 11: three-week schedule; paclitaxel 100-400 mg/m2
- Claim 12: weekly schedule; paclitaxel 50-250 mg/m2
- Claim 13: three-week schedule; paclitaxel 220-340 mg/m2
- Claim 15: weekly schedule; paclitaxel 100-150 mg/m2
- Claim 26: (dependent) paclitaxel about 100 mg/m2
Numeric schedule/dose claims let the patent map onto a protocol design. Competitors operating outside these numeric ranges may still be exposed under broader claims like Claim 1 (which does not require a numeric paclitaxel band).
Schedule interval requirement
- Claim 16: interval between each administration of the nanoparticle composition is no more than about a week
This becomes another protocol “design-around” axis. However, note Claim 16 is dependent only on Claim 1; it can be asserted independently of the weekly vs three-week dependent numeric schedule claims.
Where are the strongest “infringement entry points”?
Entry point A: Claim 1 plus “cremophor-free” albumin-coated paclitaxel nanoparticles + cisplatin/carboplatin
The broadest method coverage is Claim 1. The key risk test for any NSCLC program:
- Are the paclitaxel nanoparticles albumin-coated?
- Are they free of cremophor?
- Is the platinum agent cisplatin or carboplatin?
- Is the use a treatment method in a human with NSCLC?
Entry point B: Protocol-matched dependent claims
If product development aligns with defined clinical dosing and scheduling, dependent claims become relevant:
- ≤200 nm particle size (Claim 5/20/27)
- Albumin:paclitaxel ratio ≤18:1 (Claim 17/18/21/28)
- Albumin:paclitaxel ≤9:1 and/or <9:1 (Claim 6/19/22/23/29/30)
- Advanced stage (Claim 9/25)
- Paclitaxel numeric dose bands tied to weekly or three-week regimens (Claims 11-15 and 26)
- Dosing frequency interval ≤ about one week (Claim 16)
- Timing: simultaneous vs sequential (Claims 3 and 4)
The combination of formulation-specific constraints plus explicit dosing/schedule bands tends to concentrate litigation leverage on the specific regimen mirror-image protocols.
What is the practical claim map for a competitor? (Claim coverage matrix)
1) Formulation-identity risk (Claim 1 gates)
| Feature |
Required by Claim 1? |
Dependent claims that also require it |
| Nanoparticles containing paclitaxel coated with albumin |
Yes |
Yes (foundation for most dependencies) |
| “Free of cremophor” |
Yes |
Yes (same foundation) |
| Platinum: cisplatin or carboplatin |
Yes |
Yes (cisplatin via Claim 33; carboplatin via several dependencies) |
2) Product-parameter tuning risk
| Feature |
Claim threshold(s) |
Where enforced |
| Particle size |
Avg diameter ≤ about 200 nm |
Claims 5, 20, 27 |
| Albumin:paclitaxel weight ratio |
<9:1; ≤9:1; ≤18:1 |
Claims 6, 17-19, 21-23, 28-30 |
| Albumin type |
Human serum albumin |
Claim 8 and Claim 24 |
3) Protocol risk (dose and schedule)
| Feature |
Threshold(s) |
Where enforced |
| Paclitaxel dose |
50-400 mg/m2; plus narrower bands |
Claims 10-15, 26 |
| Schedule pattern |
Weekly vs three-week |
Claims 11-13, 15, 12 |
| Time between administrations |
≤ about 1 week |
Claim 16 |
| Administration order |
Simultaneous vs sequential |
Claims 3-4 |
| Stage |
Advanced stage |
Claims 9 and 25 |
How might the patent constrain product differentiation?
Cremophor-free is the central differentiator
Because Claim 1 explicitly requires the nanoparticle composition be “free of cremophor,” any product still relying on cremophor-based excipients in the delivered nanoparticle composition would miss Claim 1 as written.
Albumin-coated nanoparticle architecture is also a differentiator
A competitor using paclitaxel nanoparticles coated with non-albumin carriers (or paclitaxel in non-nanoparticle formulations) would likely avoid the Claim 1 formulation identity requirements.
Platinum pairing keeps the method constrained
The method must include cisplatin or carboplatin. Platinum analogs outside those two compounds are not covered by the literal claim language in the portions you provided.
Patent landscape view (what this claim set signals, and where the battles will be fought)
The claim set is structured like a typical combination-protocol and formulation-parameter patent. That means the landscape will tend to cluster around:
- Albumin-paclitaxel nanoparticle formulations that are cremophor-free
- NSCLC treatment regimens pairing an albumin-paclitaxel nanoparticle with cisplatin/carboplatin
- Clinical protocol parameters: particle size, albumin:paclitaxel ratios, and paclitaxel mg/m2 dosing on weekly or three-week cycles
In practice, this kind of patent usually creates three landscape stress zones:
- Formulation developers: whether their albumin-coated paclitaxel nanoparticles are cremophor-free and meet nanoparticle size/ratio bounds.
- Clinical regimen designers: whether their paclitaxel dose and schedule match the dependent claims.
- Protocol sequencing choices: whether administration is simultaneous or sequential as characterized in the claims.
Key Takeaways
- Claim 1 is the breadth driver: it covers NSCLC treatment in humans with albumin-coated, cremophor-free paclitaxel nanoparticles plus cisplatin or carboplatin, without requiring a specific particle size, albumin:paclitaxel ratio, dose band, or schedule.
- Dependent claims narrow the infringement map using explicit thresholds: particle size ≤200 nm, albumin:paclitaxel ratios (≤18:1, ≤9:1, and <9:1), and paclitaxel dosing on weekly or three-week schedules.
- Cremophor-free and cisplatin/carboplatin pairing are the strongest literal gates.
- Protocol engineering is a secondary lever: timing (simultaneous vs sequential), interval between nanoparticle administrations (≤ about a week), and dose banding can move a regimen into or out of the most specific dependent claims.
FAQs
-
Does US 8,034,375 require a specific paclitaxel dose in the independent claim?
No. Claim 1 does not specify numeric paclitaxel mg/m2 ranges; those appear in dependent claims.
-
Is “≤200 nm” required for infringement under Claim 1?
No. Particle size appears only in dependent claims (e.g., Claim 5).
-
Can the platinum agent be cisplatin?
Yes. Claim 1 allows cisplatin or carboplatin, and Claim 33 specifies cisplatin.
-
Does the patent require cremophor-free nanoparticles?
Yes. Claim 1 requires the nanoparticle composition be “free of cremophor.”
-
Is albumin required to be human serum albumin?
Only in dependent claim 8 and claim 24. Claim 1 requires albumin-coated nanoparticles, not necessarily human serum albumin.
References (APA)
[1] User-provided claim text for US Patent 8,034,375 (claims 1-34).
